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Background: Bicuspid aortic valve (BAV) is the most frequent congenital heart disease with frequent involvement
in thoracic aortic dilatation, aneurysm and dissection. Although BAV and Marfan syndrome (MFS) share some
clinical features, and some MFS patients with BAV display mutations in FBN1, the gene encoding fibrillin-1, the
genetic background of isolated BAV is poorly defined.
Methods: Ten consecutive BAV patients [8 men, age range 24–42 years] without MFS were clinically characterized.
BAV phenotype and function, together with evaluation of aortic morphology, were comprehensively assessed by
Doppler echocardiography. Direct sequencing of each FBN1 exon with flanking intron sequences was performed on
eight patients.
Results: We detected three FBN1 mutations in two patients (aged 24 and 25 years) displaying aortic root
aneurysm ≥50 mm and moderate aortic regurgitation. In particular, one patient had two mutations
(p.Arg2726Trp and p.Arg636Gly) one of which has been previously associated with variable Marfanoid
phenotypes. The other patient showed a pArg529Gln substitution reported to be associated with an incomplete
MFS phenotype.
Conclusions: The present findings enlarge the clinical spectrum of isolated BAV to include patients with BAV
without MFS who have involvement of FBN1 gene. These results underscore the importance of accurate
phenotyping of BAV aortopathy and of clinical characterization of BAV patients, including investigation of
systemic connective tissue manifestations and genetic testing.
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Bicuspid aortic valve (BAV) is the most common congeni-
tal heart disease [1,2]. BAV and Marfan syndrome (MFS)
share some clinical features such as the increased preva-
lence of thoracic aortic aneurysm (TAA) and dissection
(TAD), as well as overlapping histopathological features
[3]. MFS is associated with mutations in the fibrillin 1
(FBN1) gene in more than 90% of patients, and less* Correspondence: guglielmina.pepe@unifi.it
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unless otherwise stated.commonly in the transforming growth factor beta receptor
2 and 1 (TGFBR2, and TGFBR1) genes [4]. While the gen-
etic background of MFS is well described at present, that
of BAV is poorly defined.
BAV has been associated with NOTCH1 gene mutations
in a few cases [5], and with actin alpha 2 smooth muscle
aorta (ACTA2) gene mutations (12%) in a subgroup of pa-
tients with TAA, livedo reticularis on the upper and lower
limbs, and iris flocculi [6]. Other genes are suspected to be
associated, and more chromosomal loci associated to BAV
have been reported [7,8].
We have recently demonstrated a 4-fold increase in
the prevalence of BAV in a large cohort of unrelated
MFS patients (12 BAV in 257 MFS, 4.7%) with respectd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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including primary school students in Italy (0.5%), detect-
ing FBN1 mutations in 2 out of 3 subjects who consented
to undergo DNA mutation analysis [9]. These findings are
consistent with data showing decreased FBN1 mRNA or
protein content in a subgroup of BAV patients [10], which
suggest that FBN1 may be one of the genes associated
with BAV.
To date, however, the demonstration of FBN1 mutations
in patients with BAV is lacking. Thus, we screened for
FBN1 mutations in the selected patients with BAV and
thoracic aortic dilation not fulfilling the clinical criteria for
MFS.
Methods
Ethical statements
The local Ethical Committee of the Medicine Faculty of
Florence approved the study protocols and participants
provided their written informed consent to participate in
this study.
Subjects
Among the 432 patients with thoracic aortic dilatation,
aneurysm, or dissection consecutively referred to the Cen-
ter for Marfan Syndrome (Careggi Hospital, Florence, Italy)
between 2001 and 2011, 22 were affected by BAV and aortic
enlargement (aortic diameter ≥40 mm), of whom 12 had
also MFS [9]. In the other ten patients, the diagnosis of
MFS was excluded according to both the old and the re-
vised Ghent criteria [4,11], and these patients constitute the
subject of the present study. We also screened a control co-
hort of 200 unrelated individuals recruited from the same
geographical area (160 male; mean age33.2 ± 8.5 years) for
the presence of the genetic variants identified in the BAV
patients with aortic enlargement. The controls were also
evaluated for the presence and familial history of connect-
ive tissue disorders, BAV and aortic dilatation/dissection.
The presence of BAV and or aortic dilatation/dissection
was excluded in controls by echocardiography.
Echocardiographic methods
All echocardiographic measurements had been made by a
senior cardiologist (C.P.). BAV was diagnosed when only
two cups were unequivocally identified in systole and dia-
stole in the short axis view with a clear “fishmouth” ap-
pearance during systole as previously described [1,12].
Aortic dimensions were assessed at end-diastole in the
parasternal long-axis view at four levels by the leading
edge method [1,12,13] and Z-scores were calculated ac-
cording to age-adjusted nomograms [13]. For patients
who had undergone aortic surgery, still-frame photo-
graphs and/or available videos were also reviewed to verify
and confirm the diagnosis of BAV. Patients for whom aor-
tic valve morphology was indeterminate were consideredas having tricuspid aortic valves. Aortic or mitral regurgi-
tation were graded by multiple criteria combining color
Doppler and continuous wave Doppler signals, and aortic
valve stenosis was graded by peak aortic valve velocity [1].
DNA extraction, polymerase chain reaction and direct
sequencing
Genomic DNA was extracted from peripheral venous
blood using FlexiGene Kit (Qiagen, Germany). The 65
exons of FBN1 gene with the intronic flanking regions
were amplified by polymerase chain reaction (PCR) [14].
PCR products were directly sequenced [14].
DNA samples from 200 healthy individuals were
screened to determine whether the mutations identified
in this study were present in a control population by direct
sequencing of the exons in which the three mutations were
identified. Prediction of the effect of mutations was per-
formed by Polyphen-2 (http://genetics.bwh.harvard.edu/
pph2/), Sorting Tolerant From Intolerant (SIFT, http://sift.
jcvi.org) and MuPro (http://www.igb.uci.edu/~baldig/muta-
tion.html) algorithms.
Results
All patients [8 men and 2 women, age range 24–42 years]
were Italian. Two of them (P8 and P10) (Table 1) had
MASS syndrome (an acronym for myopia, mitral valve
prolapse, aortic dilatation, skeleton features, skin features);
most displayed systemic features such as pectus excava-
tum, scoliosis, pes planus, cutaneous striae, mitral valve
prolapse and myopia (Table 1). All had fusion of the right
and left coronary aortic valve cusps, and 8 of 10 patients
had maximum aortic enlargement at the level of the aortic
root and not at the ascending aorta.
FBN1 gene mutation analysis
Mutations analysis was performed on 8 of the 10 pa-
tients as P7 and P8 did not give consent to undergo mu-
tation screening analysis. FBN1 mutations were detected
in two patients (P1 and P2).
P1 had a c.1586G >A, p.Arg529Gln mutation that rep-
resents a basic to polar neutral charge change in exon 12
(cbEGF-like 03 domain) (Figure 1). In P2 a double muta-
tion was detected: a c.1906A >G mutation (p.Arg636Gly
basic to apolar substitution) and a c.8176C > T mutation
(p.Arg2726Trp causing a basic to apolar change); the first
located in exon 15 (cbEGF-like 06 domain), the second in
exon 64 (COOH unique region) (Figure 1). The three mu-
tations were not present in 400 alleles among Italian con-
trols. No mutations were detected in the other 6 patients.
Discussion
To the best of our knowledge, this is the first study
reporting pathogenetic fibrillin 1 mutations in patients
with BAV and aortic dilatation/aneurysm in whom MFS
Table 1 Clinical and molecular characteristics of the 10 studied patients
Patients
ID
Age at diagnosis/referred
to our center (years) Sex
Diagnostic criteria
BAV morphology MAS: diameter(mm)/site BAV hemodynamics MVP Eye EL
Systemic
features
Systemic
features score Family history
FBN1
mutations
P1 15/24 M RL 50/AoR AR moderate - - - 0 TAA Arg529Gln
P2 19/25 M RL 57/AoR AR moderate + - MVP, My 2 -
Arg636Gly
Arg2726Trp
P3 35/40 M RL 45/AoR - - - My, PE, Sc, Th+ 4 - -
P4 27/40 F RL 41/AoR AR mild + - MVP, PP, CS 3 TAA/AAA -
P5 17/24 M RL 47/AscA - - - Sc, PP, CS 3 - -
P6 40/40 M RL 44/AoR - - - PE, CS, facies 3 - -
P7 42/42 M RL Prothesic tube - - - CS 1 - na
P8 31/31 M RL 42/AscA - + - MVP, PE, PC, PP, CS 6 BAV na
P9 24/24 M RL 40/AoR - - - PE, Ky, CS, My 4 TAA -
P10 31/31 F RL 48/AoR AR mild + - MVP, CS, DE, PP, Sc 5 - -
ID = identification number; BAV = bicuspid aortic valve; MAS =maximal aortic size; M =male; F = female; MVP =mitral valve prolapse; RL = fusion of right and left coronary leaflets; EL = ectopia lentis; AoR = aortic root;
AR = aortic regurgitation; AscA = Ascending aorta; Systemic features are reported and quoted according to new Ghent criteria (Loeys’ et al. 2010); CS = cutaneous Striae; EL = ectopia lentis; HD = hindfoot deformities;
My =myopia; PE = pectus excavatum, ; PP = pes planus; Sc = scoliosis;Ky = kyphosis; Th + =positive thumb sign; + = present; - = absent; na = not analyzed.
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Figure 1 Identification of FBN1 mutations in BAV patients. A: Sequence chromatogram showing c.1586 G > A (p. Arg529Gln) mutation,
identified in P1 patient. B1/B2: Sequence chromatograms showing c.1906 A > G (p. Arg636Gly) and c.8176C > T (p. Arg2726Trp) mutations,
identified in P2 patients. Arrows indicate the locations of the point mutations.
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ally excluded according to the updated Ghent criteria [4].
The mutations detected in two unrelated patients are all
arginine substitutions. The Arg529Gln mutation detected
in P1 is reported at the UMD-FBN1 database (http://www.
umd.be/FBN1/4DACTION/WV/2451) in a male proband
of France geographic origin with an incomplete MFS
phenotype. Unfortunately, no further information on BAV
occurrence in this patient is available. Moreover, a single
nucleotide substitution in the same codon causing a preter-
minal stop codon was previously described in a Norwegian
patient displaying a classic Marfan phenotype with ectopia
lentis, thoracic aorta dilatation and systemic features [15].
According to Polyphen-2 and MuPro, the Arg529Gln mu-
tation is probably damaging and contributes to decreased
protein stability. P2 carried two mutations, one of which
(Arg2726Trp) has been previously associated with variable
clinical phenotypes, including mitral valve prolapse and
myopia [14], isolated skeletal features [16], combined skel-
etal and ocular manifestations [17], mild skeletal abnormal-
ities [18]; and a family in which the mutation appeared
incompletely penetrant [19]. The Arg2726Trp mutation
was reported in one chromosome in 1000Genomes and
NHLBI Exome Variant Server databases as rs61746008
(http://www.1000genomes.org/ and http://evs.gs.washing-
ton.edu/EVS/). The other mutation (Arg636Gly) identifiedin P2 has never been reported in the literature, although
another single nucleotide substitution responsible for a dif-
ferent aminoacid change at the same codon (Arg636Ile) in
a MFS patient with aortic root dilatation, ectopia lentis and
minor involvement of skeleton was previously described
[17]. According to SIFT, both the Arg2726Trp and Arg636-
Gly mutations are classified as damaging, with decreased
protein stability as evaluated in silico by MuPro.
It is unknown at present if the two mutations at the
FBN1 locus identified in our patient are in cis, on the
same chromosome, or in trans. The infrequent presence
of double mutations has been reported in many human
gene-causing diseases such as hypertrophic cardiomyop-
athy [20,21] and arrhythmias associated with the lamin
A/C (LMNA) gene [22].
The detection of FBN1 point mutations in patients with
BAV with aortic dilatation/aneurysm but without MFS
adds to the striking clinical heterogeneity of type I fibrilli-
nopathies to include a small number of patients bearing
the most common congenital heart disease. These data
also provide further evidence of the heterogeneity of the
BAV syndrome [12], with demonstration that aortic dilata-
tion/aneurysm develops in a subgroup of patients as a
manifestation of an inherited connective tissue disorder,
including FBN1 mutations in a minority of patients. It is
noteworthy that the two patients carrying the mutations
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other, without systemic features which were otherwise
prevalent in the remaining subjects. Moreover, both had
aortic aneurysm size attaining the threshold for surgery
notwithstanding the young age [23,24], with the largest
diameter localized at the level of the sinuses of Valsalva,
which is the less prevalent phenotype of aortic dilatation in
BAV individuals [1,25]. Della Corte, et al., first named this
pattern as “root phenotype” [25] and have subsequently
demonstrated that it may be a marker of more severe aor-
topathy warranting closer surveillance [26]. Interestingly, 8
out of our 10 patients displayed this phenotype, in associ-
ation with a certain degree of systemic characteristics sug-
gestive of a connective tissue disorder. Finally, the 2
patients bearing FBN1 mutations had significant aortic re-
gurgitation, which is a powerful predictor of loss of aortic
medial elastic fibers in patients with ascending aortic aneu-
rysms and aortic valve disease [27]. These findings call for
greater focus on the BAV-related cardiovascular abnormal-
ities rather than on the MFS-like systemic features, which
may well coexist and warrant investigation in BAV patients
in general, but are not associated with the FBN1 mutations
identified in the present study. On the other hand, these
FBN1 mutations do not completely fulfill the definition of
the major criterion for MFS according to the revised Ghent
criteria because they have never been detected in Marfan
patients with TAA [4]. Therefore our two BAV/TAA pa-
tients did not achieve the diagnosis of MFS.
The FBN1 gene has been previously associated
with various conditions, including MFS, neonatal MFS,
Shprintzen-Goldberg syndrome, marfanoid neonatal proger-
oid syndrome, familial arachnodactyly, ectopia lentis, iso-
lated ascending aortic aneurysm and dissection, aortic root
dilatation without dissection, skeletal and skin abnormalities
(MASS phenotype), Marfan-like syndromes, autosomal
dominant Weill-Marchesani syndrome (WMS), mitral valve
prolapse, and sclerodermia. Recently, mutations in the
FBN1 gene were reported in two other syndromes [28,29].
The interfamilial clinical heterogeneity at the FBN1 locus is
further characterized by a striking intrafamilial variability
(OMIM*134797).
Contrasting data have been reported regarding the gen-
etic background of BAV-related aortopathy. A decrease in
FBN1 mRNA and protein has been demonstrated in some
BAV patients suggesting a possible involvement of FBN1
with BAV [10]. Moreover, single nucleotide polymorphisms
(SNPs) spread in the area of the FBN1 gene, which predis-
pose to TAA, have been reported [30]. On the other hand,
other investigators have screened BAV patients for muta-
tions in FBN1, TGFBR2, and TGFBR1 genes and failed to
detect any mutation, concluding that the FBN1 gene is not,
or only rarely, associated with BAV [31]. More recently, a
mutation in the TGFBR2 gene was reported in a patient
classified as aortic dilatation/aneurysm but otherwise notwell defined clinically [32]. Another recent study, compar-
ing gene expression in subjects with BAV and tricuspid aor-
tic valves, reported an increase of FBN1 mRNA only in the
subjects with tricuspid aortic valves [33]. Thus, it is con-
ceivable that BAV represents the phenotypic manifestation
of many distinct clinical outliers underlined by genetic, mo-
lecular, and structural anomalies that do not follow a com-
mon path [7].
At present we cannot exclude a coincidence of a com-
mon trait such as BAV in males and a rare trait like
MFS in our patients. In fact, a limitation of our study is
the lack of genomic DNA from parents and other rela-
tives of the two patients carrying mutations in FBN1
gene to demonstrate their segregation with BAV in the
two families. Another limitation of our study is the use
of transthoracic echocardiography for the ascertainment
of BAV rather than advanced imaging methods. How-
ever, the echocardiographic evaluation of our patients
was performed by an operator with a wide experience in
BAV diagnosis.
Our findings may have relevant clinical implications in
the future, if confirmed by larger studies. Although mul-
tiple similarities have been shown between MFS and BAV
patients, recent improvements in knowledge regarding the
natural history of the aortopathy in BAV [34-36] have
raised concerns regarding the direct application of surgical
criteria adopted in MFS patients to those with BAV and
aortic dilatation/aneurysm [37,38]. On the other hand,
cardiovascular events are considerable in patients with
FBN1 mutations and remain so throughout life, with men
appearing to be at higher risk for an aortic event than
women [39]. While we acknowledge that the size of the
present study and its retrospective nature do not allow
conclusions regarding the indications for surgery, our
findings support the need of future studies aimed to
characterize BAV patients with aortic dilatation/aneurysm
on the basis of their aortic phenotype and other clinical
stigmata of connective tissue disorders, eventually per-
forming genetic testing when appropriate. Whether such
an approach would result in a different outcome, thus af-
fecting therapeutic choices in patients with BAV and aortic
dilatation/aneurysm, should be a pivotal aim of such fu-
ture research.
Conclusions
The novel implication of the present findings is the need
of a multidisciplinary approach (including internal medi-
cine, medical genetics, cardiology, ophthalmology, cardio-
vascular surgery, orthopaedic, and molecular biology
experts) in the global assessment and management of pa-
tients with BAV. Due to the high prevalence of this dis-
order and its multispecialty requirements, our findings
suggest a tailored diagnostic and therapeutic approach,
which should be addressed in future prospective studies.
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that BAV is a heterogenous disorder with a wide spectrum
of clinical manifestations. Beyond the common phenotype
of isolated BAV and the previously reported association of
BAV in MFS patients [9], we described BAV patients in
whom the clinical diagnosis of MFS has been excluded,
carrying mutations in FBN1 gene. These data also expands
the clinical spectrum of the type 1 fibrillinopathies to in-
clude BAV. These results underscore the importance of
accurate clinical characterization of BAV aortopathy, in-
cluding investigation of systemic connective tissue mani-
festations and genetic testing.
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